Compare EXP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXP | ERAS |
|---|---|---|
| Founded | 1963 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.3B |
| IPO Year | 1994 | 2021 |
| Metric | EXP | ERAS |
|---|---|---|
| Price | $191.66 | $16.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $227.11 | $14.25 |
| AVG Volume (30 Days) | 294.1K | ★ 3.3M |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 3.29 | N/A |
| Revenue | ★ $495,023,000.00 | N/A |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | $59.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $171.99 | $1.53 |
| 52 Week High | $245.53 | $24.28 |
| Indicator | EXP | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 40.99 |
| Support Level | $188.79 | $12.36 |
| Resistance Level | $226.04 | $18.71 |
| Average True Range (ATR) | 5.14 | 1.20 |
| MACD | -0.72 | -0.24 |
| Stochastic Oscillator | 10.69 | 15.04 |
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.